TP53 and neoplasm: Interestingly, since MDM2 is an E3 ligase itself, MDM2-recruiting PROTAC are being developed to target itself and other pro-tumorigenic proteins to maximize p53-dependent and -independent effects in tumor suppression (Hines et al., 2019; He et al., 2021).